HC Wainwright Reaffirms “Buy” Rating for iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $46.00 target price on the stock. HC Wainwright also issued estimates for iTeos Therapeutics’ FY2029 earnings at $1.19 EPS.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company lowered their target price on shares of iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, December 19th. Wedbush reissued an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday.

iTeos Therapeutics Stock Performance

ITOS opened at $7.05 on Thursday. The firm’s 50-day simple moving average is $7.52 and its 200-day simple moving average is $9.48. iTeos Therapeutics has a twelve month low of $6.67 and a twelve month high of $18.75. The firm has a market cap of $257.56 million, a price-to-earnings ratio of -2.24 and a beta of 1.38.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.13. As a group, sell-side analysts anticipate that iTeos Therapeutics will post -3.49 EPS for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd bought a new stake in iTeos Therapeutics during the 3rd quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics during the 4th quarter worth about $42,000. Virtus ETF Advisers LLC grew its holdings in iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock worth $69,000 after acquiring an additional 3,293 shares during the last quarter. Forefront Analytics LLC bought a new stake in iTeos Therapeutics during the 4th quarter worth about $85,000. Finally, Graham Capital Management L.P. acquired a new position in iTeos Therapeutics during the 4th quarter valued at about $85,000. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.